S&P 500   4,167.00 (-0.92%)
DOW   32,789.04 (-0.77%)
QQQ   347.09 (-0.83%)
AAPL   178.12 (+0.46%)
MSFT   329.71 (-0.45%)
META   262.69 (+0.06%)
GOOGL   122.92 (-0.61%)
AMZN   119.46 (-1.81%)
TSLA   196.09 (-2.52%)
NVDA   388.15 (-3.23%)
NIO   7.24 (-2.29%)
BABA   78.14 (-0.67%)
AMD   120.61 (-3.72%)
T   15.80 (+1.02%)
F   12.09 (-3.97%)
MU   68.46 (-4.51%)
CGC   0.80 (-5.86%)
GE   100.04 (-2.30%)
DIS   87.39 (-0.49%)
AMC   4.50 (-2.81%)
PFE   37.88 (+2.35%)
PYPL   61.45 (-0.97%)
NFLX   392.57 (-0.10%)
S&P 500   4,167.00 (-0.92%)
DOW   32,789.04 (-0.77%)
QQQ   347.09 (-0.83%)
AAPL   178.12 (+0.46%)
MSFT   329.71 (-0.45%)
META   262.69 (+0.06%)
GOOGL   122.92 (-0.61%)
AMZN   119.46 (-1.81%)
TSLA   196.09 (-2.52%)
NVDA   388.15 (-3.23%)
NIO   7.24 (-2.29%)
BABA   78.14 (-0.67%)
AMD   120.61 (-3.72%)
T   15.80 (+1.02%)
F   12.09 (-3.97%)
MU   68.46 (-4.51%)
CGC   0.80 (-5.86%)
GE   100.04 (-2.30%)
DIS   87.39 (-0.49%)
AMC   4.50 (-2.81%)
PFE   37.88 (+2.35%)
PYPL   61.45 (-0.97%)
NFLX   392.57 (-0.10%)
S&P 500   4,167.00 (-0.92%)
DOW   32,789.04 (-0.77%)
QQQ   347.09 (-0.83%)
AAPL   178.12 (+0.46%)
MSFT   329.71 (-0.45%)
META   262.69 (+0.06%)
GOOGL   122.92 (-0.61%)
AMZN   119.46 (-1.81%)
TSLA   196.09 (-2.52%)
NVDA   388.15 (-3.23%)
NIO   7.24 (-2.29%)
BABA   78.14 (-0.67%)
AMD   120.61 (-3.72%)
T   15.80 (+1.02%)
F   12.09 (-3.97%)
MU   68.46 (-4.51%)
CGC   0.80 (-5.86%)
GE   100.04 (-2.30%)
DIS   87.39 (-0.49%)
AMC   4.50 (-2.81%)
PFE   37.88 (+2.35%)
PYPL   61.45 (-0.97%)
NFLX   392.57 (-0.10%)
S&P 500   4,167.00 (-0.92%)
DOW   32,789.04 (-0.77%)
QQQ   347.09 (-0.83%)
AAPL   178.12 (+0.46%)
MSFT   329.71 (-0.45%)
META   262.69 (+0.06%)
GOOGL   122.92 (-0.61%)
AMZN   119.46 (-1.81%)
TSLA   196.09 (-2.52%)
NVDA   388.15 (-3.23%)
NIO   7.24 (-2.29%)
BABA   78.14 (-0.67%)
AMD   120.61 (-3.72%)
T   15.80 (+1.02%)
F   12.09 (-3.97%)
MU   68.46 (-4.51%)
CGC   0.80 (-5.86%)
GE   100.04 (-2.30%)
DIS   87.39 (-0.49%)
AMC   4.50 (-2.81%)
PFE   37.88 (+2.35%)
PYPL   61.45 (-0.97%)
NFLX   392.57 (-0.10%)
NYSEAMERICAN:AMPE

Ampio Pharmaceuticals (AMPE) Stock Forecast, Price & News

$0.30
+0.01 (+5.10%)
(As of 11:16 AM ET)
Compare
Today's Range
$0.29
▼
$0.31
50-Day Range
$0.20
▼
$0.30
52-Week Range
$0.18
▼
$3.94
Volume
36,324 shs
Average Volume
287,601 shs
Market Capitalization
$4.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Ampio Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
5.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of Ampio Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$33,298 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.32 out of 5 stars

See Top Rated MarketRank™ Stocks Here

AMPE stock logo

About Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Stock

Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease. The company was founded by David Bar-Or in December 2008 and is headquartered in Englewood, CO.

Receive AMPE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ampio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPE Stock News Headlines

May 26, 2023 | finance.yahoo.com
Ampio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common Stock
May 15, 2023 | americanbankingnews.com
Insider Buying: Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) Director Purchases $11,000.00 in Stock
May 31, 2023 | Edge On The Street (Ad)
Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
May 6, 2023 | americanbankingnews.com
StockNews.com Begins Coverage on Ampio Pharmaceuticals (NYSE:AMPE)
April 28, 2023 | americanbankingnews.com
Ampio Pharmaceuticals (NYSE:AMPE) Research Coverage Started at StockNews.com
April 22, 2023 | americanbankingnews.com
Ampio Pharmaceuticals (NYSE:AMPE) Earns Sell Rating from Analysts at StockNews.com
April 18, 2023 | seekingalpha.com
Ampio stock jumps ~20% after CEO letter on drug program, reorganization
April 14, 2023 | americanbankingnews.com
Ampio Pharmaceuticals (NYSE:AMPE) Coverage Initiated by Analysts at StockNews.com
May 31, 2023 | Edge On The Street (Ad)
The Ignored EV Story Few Investors Know About
Lithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.
April 14, 2023 | americanbankingnews.com
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Now Covered by Analysts at StockNews.com
April 14, 2023 | americanbankingnews.com
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Now Covered by StockNews.com
April 13, 2023 | americanbankingnews.com
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Earns Sell Rating from Analysts at StockNews.com
April 12, 2023 | americanbankingnews.com
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Coverage Initiated by Analysts at StockNews.com
April 11, 2023 | americanbankingnews.com
StockNews.com Initiates Coverage on Ampio Pharmaceuticals (NYSEAMERICAN:AMPE)
April 9, 2023 | americanbankingnews.com
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Coverage Initiated at StockNews.com
April 6, 2023 | americanbankingnews.com
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Receives New Coverage from Analysts at StockNews.com
April 4, 2023 | americanbankingnews.com
StockNews.com Begins Coverage on Ampio Pharmaceuticals (NYSEAMERICAN:AMPE)
April 3, 2023 | thestreet.com
Ampio Too Busy to Tell Investors Results of Eye Drug Study
February 9, 2023 | thestreet.com
Why Ampio Pharmaceuticals (AMPE) Stock Is Plummeting Today
February 7, 2023 | wsj.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Ampio Pharmaceuticals, Inc.
December 27, 2022 | finance.yahoo.com
Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
November 17, 2022 | finance.yahoo.com
Ampio Pharmaceuticals Announces NYSE American Removal of Trading Suspension
November 8, 2022 | finance.yahoo.com
Ampio Pharmaceuticals Announces Fifteen-to-One Reverse Stock Split
October 16, 2022 | stockhouse.com
MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
October 16, 2022 | prnewswire.com
AMPE DEADLINE TOMORROW: ROSEN, skilled investor counsel, Encourages Ampio Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important October 17 Deadline in Securities Class Action - AMPE
October 12, 2022 | benzinga.com
MONDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
October 7, 2022 | prnewswire.com
ROSEN, LEADING INVESTOR COUNSEL, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMPE
See More Headlines
Receive AMPE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ampio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPE Company Calendar

Last Earnings
5/08/2023
Today
5/31/2023
Next Earnings (Estimated)
8/07/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NYSEAMERICAN:AMPE
Previous Symbol
NYSE:AMPE
CUSIP
03209T10
CIK
1411906
Web
ampiopharma.com
Phone
(720) 437-6500
Fax
720-437-6501
Employees
20
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.8493)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-17,080,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-97.46%
Return on Assets
-69.15%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.67
Quick Ratio
4.67

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.02 per share
Price / Book
0.14

Miscellaneous

Outstanding Shares
15,093,000
Free Float
14,960,000
Market Cap
$4.40 million
Optionable
Optionable
Beta
1.48

Key Executives

  • Michael A. Martino
    Chief Executive Officer & Director
  • Daniel G. Stokely
    Chief Financial Officer & Secretary
  • Howard Levy
    Chief Medical Officer
  • Lane Hapke
    Vice President-Manufacturing Operations
  • Laura Goldberg
    Vice President-Quality & Regulatory Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AMPE Stock - Frequently Asked Questions

How have AMPE shares performed in 2023?

Ampio Pharmaceuticals' stock was trading at $0.2252 on January 1st, 2023. Since then, AMPE shares have increased by 29.4% and is now trading at $0.2915.
View the best growth stocks for 2023 here.

When is Ampio Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our AMPE earnings forecast.

How were Ampio Pharmaceuticals' earnings last quarter?

Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) announced its quarterly earnings data on Monday, May, 8th. The specialty pharmaceutical company reported ($0.26) earnings per share for the quarter.

What other stocks do shareholders of Ampio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ampio Pharmaceuticals investors own include Trevena (TRVN), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Rigel Pharmaceuticals (RIGL), Cogent Biosciences (UMRX), ADMA Biologics (ADMA), Great Panther Mining (GPL), Zosano Pharma (ZSAN) and Miragen Therapeutics (MGEN).

What is Ampio Pharmaceuticals' stock symbol?

Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AMPE."

Who are Ampio Pharmaceuticals' major shareholders?

Ampio Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include HRT Financial LP (1.44%). Insiders that own company stock include Dan Stokely, David R Stevens, Holli Cherevka, Michael A Martino and Philip H Coelho.
View institutional ownership trends.

How do I buy shares of Ampio Pharmaceuticals?

Shares of AMPE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ampio Pharmaceuticals' stock price today?

One share of AMPE stock can currently be purchased for approximately $0.29.

How much money does Ampio Pharmaceuticals make?

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) has a market capitalization of $4.40 million. The specialty pharmaceutical company earns $-17,080,000.00 in net income (profit) each year or ($1.8493) on an earnings per share basis.

How can I contact Ampio Pharmaceuticals?

Ampio Pharmaceuticals' mailing address is 373 Inverness Pkwy Ste 200, ENGLEWOOD, CO 80112-5898, United States. The official website for the company is ampiopharma.com. The specialty pharmaceutical company can be reached via phone at (720) 437-6500, via email at info@ampiopharma.com, or via fax at 720-437-6501.

This page (NYSEAMERICAN:AMPE) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -